文献速递自身免疫性与大疱性皮肤病

二肽基肽酶-4抑制剂是大疱性类天疱疮的危险因素:法国与瑞士回顾性多中心病例对照研究

Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland.
PubMed 文献 · J Am Acad Dermatol · 2017-12-21

停用DPP4i并启动一线治疗后95%病例临床缓解。

要点

  • DPP4i与糖尿病患者的BP风险升高相关,维格列汀关联最强。
  • 男性及80岁及以上患者中关联更强,属高危人群。
  • 停用DPP4i并启动一线治疗可使95%病例临床缓解。

核心结论

  • DPP4i尤其维格列汀与BP发生风险升高相关,使用需谨慎评估,尤其男性及80岁及以上高危患者。

研究设计与样本

  • 法国与瑞士皮肤科2014年1月1日至2016年7月31日回顾性1:2病例对照研究,纳入61例糖尿病合并BP病例和122例年龄性别匹配的糖尿病对照。

主要发现

  • 分层分析显示男性和80岁及以上患者关联更强。
  • 停用DPP4i并启动一线治疗后95%病例临床缓解。

临床怎么用

  • 对使用DPP4i的糖尿病患者应警惕BP发生,尤其男性和80岁及以上患者。
  • 疑诊DPP4i相关BP时应评估停药并启动一线治疗。

局限性

  • 回顾性研究,来自三级转诊医院。
  • 分析仅关注DPP4i摄入,未分析二甲双胍的潜在独立效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Case reports have suggested an association between dipeptidyl peptidase-4 inhibitors (DPP4is) and development of bullous pemphigoid (BP). OBJECTIVE: To evaluate the association between DPP4i treatment and development of BP. METHODS: We conducted a retrospective 1:2 case-control study, comparing case patients with diabetes and BP with age- and sex-matched control patients with diabetes issued from Swiss (Bern) and French (Marseille) dermatologic departments from January 1, 2014, to July 31, 2016. RESULTS: We collected 61 case patients with diabetes and BP and 122 controls. DPP4is were associated with an increased risk for development of BP (adjusted odds ratio, 2.64; 95% confidence interval, 1.19-5.85; P = .02), with vildagliptin showing the highest adjusted odds ratio (3.57 [95% confidence interval, 1.07-11.84; P = .04]). Stratified analysis showed a stronger association in males and patients age 80 years or older. DPP4i withdrawal and the initiation of first-line treatments led to clinical remission in 95% of cases. LIMITATIONS: This was a retrospective study in tertiary referral hospitals. We focused the analysis on DPP4i intake, without analyzing the potential isolated effect of metformin. CONCLUSIONS: DPP4is, especially vildagliptin, are associated with an increased risk for development of BP. Their use needs to be carefully evaluated, particularly in high-risk patients, such as males and those age 80 years or older.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Benzaquen M, Borradori L, Berbis P, et al. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland. J Am Acad Dermatol. 2017. PMID: 29274348. doi:10.1016/j.jaad.2017.12.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。